infection. In 1994, Roberts et al designed two virus-specific CARs using CD4 or a single chain 73 antibody as binding domains for recombinant gp120 on the surface of cells (1), and these were 74 shown subsequently to have direct capacity to kill HIV-1-infected cells and suppress viral 75 replication at levels similar to HIV-1-specific CTL clones isolated from infected persons (2) . 76
Based on these data, the CD4-based CAR, consisting of the CD4 extracellular and 77 transmembrane domains fused to the CD3 ζ intracellular signaling domain (CD4-ζ), was 78 advanced to clinical trials starting in the late 1990s, using retroviral transduction of autologous 79 peripheral blood T lymphocytes and reinfusion. Unfortunately this effort was abandoned after 80 these trials showed safety but no clear benefits; one study in viremic subjects showed no 81 reduction in viremia although there appeared to be lowered rectal tissue virus burden others, although more testing will be required. Given an optimal range of affinity for CARs 300 against their target proteins, where higher or lower levels of affinity yield inferior activity (25), it 301 may be that CARs will differ in their persistence depending on their affinity for the specific HIV-302 1 Env sequence encountered in vivo. In this regard, the demonstration by Webb et al (26) that 303 different bnAbs have highly variable neutralization curve slopes might suggest that bnAbs with a 304 flatter slope would have a larger "sweet spot" of affinity across varying HIV-1 Envs. They 305 reported that CD4-binding site (including VRC01 and 3BNC117) and V3-glycan (including 306 PGT128) bnAbs exhibit steeper slopes, while V2-glycan (including PG9) and MPER (including 307 10E8) bnAbs exhibit flatter slopes. However, this appears to be contradicted by our observation 308 that the PG9-and 10E8-based CARs seem to have less breadth of antiviral activity than the 309 VRC01-and 3BNC117-based CARs, suggesting the influence of other potential factors such as 310 preservation of affinity in single chain form and/or greater reserve of affinity. Further supporting 311 this point, while X5 was originally considered broadly-neutralizing, it has relatively poor 312 neutralizing breadth against varying HIV-1 isolates compared to the other antibodies tested here 313 
